NCI Receives Regulatory Approval for New Independent Director Appointment
Stock News
Aug 28
New China Life Insurance Company Ltd. (01336) has announced that it has received official approval from the National Financial Regulatory Administration regarding the qualification of Ms. Zhang Xiufen as an independent director of the company.
According to the company's latest announcement, the regulatory body has issued Document No. Jin Fu [2026] 470, formally endorsing Ms. Zhang's appointment as an independent non-executive director. Her tenure in this role, along with her positions on the board's specialized committees, will commence on August 25, 2026, and will continue until the expiration of the company's ninth board term.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.